Type 2 diabetes lifestyle study tests diet and exercise in a feasibility trial — LiveFuture News
Open on LiveFuture.ai →

Type 2 diabetes lifestyle study tests diet and exercise in a feasibility trial

A ClinicalTrials.gov registry observation shows a randomized feasibility study in people with type 2 diabetes comparing CH-rich and CH-reduced diets, both paired with exercise, with completion estimated for 2027-03.

A randomized feasibility study in people with type 2 diabetes is now listed as ACTIVE_NOT_RECRUITING, and that is the clearest current signal in the update. The study, sponsored by Steno Diabetes Center Copenhagen, compares two lifestyle approaches: CH-rich diet with exercise and CH-reduced diet with exercise. For readers, the main point is simple: this is a test of whether a structured, non-drug program can be carried out in practice, not a claim that one approach has already worked better.

The registry observation was published 2026-11-18T00:00:00+00:00, and the estimated primary completion date is 2027-03. Because this is a feasibility study, the emphasis is on whether the plan can be followed, measured, and delivered reliably. The record says there are no results posted yet, so the study remains a work in progress rather than a finished comparison.

"Feasibility testing of diet adherence"

What the study is measuring

The trial is randomized and splits participants between the two diet-and-exercise arms. Diet adherence is checked with myfood24 dietary recalls collected over three consecutive days at set time points, and a recall day counts as adherent if carbohydrate intake is within the arm-specific target ±10 E%. That makes the study less about broad promises and more about whether people can actually stay within the planned diet pattern over time.

Exercise adherence is also built into the design, with 3 sessions pr. week, from week 13 to 52. The record says adherence is assessed through self-report and a wearable heart rate monitor using the study app, with completion calculated as completed sessions divided by total prescribed sessions. In other words, the study is tracking both what participants say they did and what the device-based record shows.

Why feasibility matters here

Several of the primary outcomes focus on practical questions around recruitment and retention. The study will count how many people express interest, complete screening, are included, drop out, or finish, and it will document reasons for exclusion or withdrawal. It will also look at GP recruitment and safety procedures, including interest, instruction, collaboration agreements, and safety-related contacts and medication changes.

The record also includes qualitative checks: interviews with one GP or staff member from each participating clinic, plus observation of group-based diet and exercise sessions. Those notes are meant to capture barriers, opportunities, and unintended consequences, which suggests the study is trying to understand not just whether the program can be assigned, but whether it can be run smoothly in real clinical settings.

How it fits the wider obesity and metabolic landscape

This update also sits within the broader live Obesity & Metabolic special event, where other clinical trial observations cover topics ranging from obesity and overweight to diabetes-related treatment questions. The shared thread is a field that keeps testing both medication-based and non-pharmacological approaches at the same time. The diet-and-exercise study stands out because it centers on routine behavior changes and on the logistics of delivering them.

For readers following type 2 diabetes research, the useful takeaway is that the trial is built to answer a practical question first: can this lifestyle program be followed well enough to study properly? The stronger clinical question of effectiveness is not settled by this record. What it does show is that the study is active, structured, and being measured carefully through 2027-03.